Literature DB >> 3933709

Long term effects of cyclophosphamide on testicular function.

A R Watson, C P Rance, J Bain.   

Abstract

Thirty men treated in childhood with cyclophosphamide for a mean of 280 days were assessed at a mean of 12.8 years after treatment for hormone concentrations and spermatogenesis. Four were azoospermic, nine oligospermic, and 17 normospermic. There was a significant inverse correlation of sperm density with cyclophosphamide dosage and duration of treatment. After a further mean follow up of 7.2 years three patients who were previously oligospermic and one who was azoospermic had normal sperm counts. All patients had normal sexual characteristics and libido. Serum androgen and prolactin concentrations did not differ significantly between patients and controls. Raised basal and stimulated follicle stimulating hormone concentrations were in keeping with impaired spermatogenesis. All patients had significantly raised luteinising hormone responses on stimulation with luteinising hormone releasing hormone. The results suggest compensated Leydig cell failure, and patients with this condition require long term evaluation of testicular function. Potential recovery of spermatogenesis with time requires appropriate counselling and contraceptive advice.

Entities:  

Mesh:

Substances:

Year:  1985        PMID: 3933709      PMCID: PMC1418091          DOI: 10.1136/bmj.291.6507.1457

Source DB:  PubMed          Journal:  Br Med J (Clin Res Ed)        ISSN: 0267-0623


  24 in total

1.  Cyclophosphamide and the pubertal testis.

Authors:  J Rapola; O Koskimies; N P Huttunen; P Floman; J Vilska; N Hallman
Journal:  Lancet       Date:  1973-01-13       Impact factor: 79.321

2.  Sterility and testicular atrophy related to cyclophosphamide therapy.

Authors:  K F Fairley; J U Barrie; W Johnson
Journal:  Lancet       Date:  1972-03-11       Impact factor: 79.321

3.  Cyclophosphamide and the prepubertal testis.

Authors:  G C Arneil
Journal:  Lancet       Date:  1972-12-09       Impact factor: 79.321

4.  Cyclophosphamide and reproductive function.

Authors:  R Kumar; J D Biggart; J McEvoy; M G McGeown
Journal:  Lancet       Date:  1972-06-03       Impact factor: 79.321

5.  Controlled trial of cyclophosphamide in steroid-sensitive relapsing nephrotic syndrome of childhood.

Authors:  T M Barratt; J F Soothill
Journal:  Lancet       Date:  1970-09-05       Impact factor: 79.321

6.  Testicular function in prepubertal and pubertal male patients treated with cyclophosphamide for nephrotic syndrome.

Authors:  J Penso; B Lippe; R Ehrlich; F G Smith
Journal:  J Pediatr       Date:  1974-06       Impact factor: 4.406

7.  A controlled prospective study of cyclophosphamide in relapsing, corticosteroid-responsive, minimal-lesion nephrotic syndrome in childhood.

Authors:  J Chiu; P N McLaine; K N Drummond
Journal:  J Pediatr       Date:  1973-04       Impact factor: 4.406

8.  Monotropic increase of serum FSH correlated with low sperm count in young men with idiopathic oligospermia and aspermia.

Authors:  S W Rosen; B D Weintraub
Journal:  J Clin Endocrinol Metab       Date:  1971-03       Impact factor: 5.958

9.  Gonadal function in children with nephrosis treated with cyclophosphamide.

Authors:  A J Pennisi; C M Grushkin; E Lieberman
Journal:  Am J Dis Child       Date:  1975-03

10.  Return of spermatogenesis after stopping cyclophosphamide therapy.

Authors:  J D Buchanan; K F Fairley; J U Barrie
Journal:  Lancet       Date:  1975-07-26       Impact factor: 79.321

View more
  20 in total

1.  Gonadal function of young adults after therapy of malignancies during childhood or adolescence.

Authors:  H L Müller; M Klinkhammer-Schalke; B Seelbach-Göbel; A A Hartmann; J Kühl
Journal:  Eur J Pediatr       Date:  1996-09       Impact factor: 3.183

Review 2.  Therapy of idiopathic membranous nephropathy.

Authors:  C Ponticelli; P Zucchelli; P Passerini
Journal:  Springer Semin Immunopathol       Date:  1987

Review 3.  Anticancer chemotherapeutic agents and testicular dysfunction.

Authors:  Kohei Yamaguchi; Masato Fujisawa
Journal:  Reprod Med Biol       Date:  2011-03-17

4.  Evaluation of spermatogenic response of mice to the induction of mutations by combined treatment with X rays and antineoplastic drugs.

Authors:  M Lenarczyk; M Dobrzyńska; M G Słowikowska; A K Gajewski
Journal:  Radiat Environ Biophys       Date:  1994       Impact factor: 1.925

Review 5.  Consensus statement on management and audit potential for steroid responsive nephrotic syndrome. Report of a Workshop by the British Association for Paediatric Nephrology and Research Unit, Royal College of Physicians.

Authors: 
Journal:  Arch Dis Child       Date:  1994-02       Impact factor: 3.791

6.  Pituitary-gonadal function in women following cyclophosphamide treatment for childhood nephrotic syndrome: long-term follow-up study.

Authors:  R Bogdanović; M Banićević; A Cvorić
Journal:  Pediatr Nephrol       Date:  1990-09       Impact factor: 3.714

7.  Testicular function following cyclophosphamide treatment for childhood nephrotic syndrome: long-term follow-up study.

Authors:  R Bogdanović; M Banićević; A Cvorić
Journal:  Pediatr Nephrol       Date:  1990-09       Impact factor: 3.714

Review 8.  Fertility preservation and management of gonadal failure associated with lymphoma therapy.

Authors:  Simon J Howell; Stephen M Shalet
Journal:  Curr Oncol Rep       Date:  2002-09       Impact factor: 5.075

9.  Fertility of male survivors of childhood cancer: a report from the Childhood Cancer Survivor Study.

Authors:  Daniel M Green; Toana Kawashima; Marilyn Stovall; Wendy Leisenring; Charles A Sklar; Ann C Mertens; Sarah S Donaldson; Julianne Byrne; Leslie L Robison
Journal:  J Clin Oncol       Date:  2009-11-30       Impact factor: 44.544

Review 10.  Cyclophosphamide and cancer: golden anniversary.

Authors:  Ashkan Emadi; Richard J Jones; Robert A Brodsky
Journal:  Nat Rev Clin Oncol       Date:  2009-09-29       Impact factor: 66.675

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.